ArticleiScience2025
Taurochenodeoxycholic acid ameliorates liver fibrosis by regulating gut microbiota and bile acids via hippo-YAP pathway.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Two Standards-Aided LC-MS Technologies Uncover 30 "Unreported" Compounds in Natural Bear Bile Powder to Add a New Pharmacopoeia Quality-Marker.Journal of separation science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholestatic liver disease is characterized by gut microbiota dysbiosis and excessive toxic hepatic bile acid accumulation. Regulation of gut microbiota and suppression of bile acid synthesis are potential strategies for the treatment of cholestatic liver disease. Fetal liver bile acids demonstrate cytoprotective properties during hepatic development, prompting investigation into their therapeutic potential in extrahepatic biliary atresia (EHBA) rats. Comparing bile acid profiles, taurochenodeoxycholic acid (TCDCA) most effectively reduced hepatic bile acids and fibrosis, while altering gut microbiota and increasing
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.